Myrna Candelaria

8PUBLICATIONS
44CO-AUTHORS
Haematological tumoursPredictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Epidemiology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 11, 2026
Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified.

|Sep 14, 2024
Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients.

Myrna Candelaria, Dennis Cerrato-Izaguirre, Olga Gutierrez

|Oct 14, 2022
ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma.

José Díaz-Chávez, Olga Gutiérrez-Hernández, Lucia Taja-Chayeb

|Jul 16, 2021
Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.

Luis Malpica, Daniel J Enriquez, Denisse A Castro

|Apr 02, 2021
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma.

Myrna Candelaria, Alfonso Dueñas-Gonzalez

|Jul 06, 2019
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.

Myrna Candelaria, Derlis E González, Marcia Torresan Delamain

Pageof 2

Frequent Collaborators

2 joint publications

Luis Malpica

2 joint publications

Brady Ernesto Beltran

2 joint publications

Denisse Castro Uriol

2 joint publications

Henry Idrobo Quintero